open access

Vol 85, No 2 (2017)
ORIGINAL PAPERS
Published online: 2017-03-12
Submitted: 2016-10-25
Accepted: 2017-02-27
Get Citation

Comorbidity in patients undergoing surgery for lung cancer. Do we have an adequate tool to assess it?

Marta Lembicz, Piotr Gabryel, Beata Brajer-Luftmann, Wojciech Dyszkiewicz, Halina Batura-Gabryel
DOI: 10.5603/ARM.2017.0011
·
Adv Respir Med 2017;85(2):55-63.

open access

Vol 85, No 2 (2017)
ORIGINAL PAPERS
Published online: 2017-03-12
Submitted: 2016-10-25
Accepted: 2017-02-27

Abstract

INTRODUCTION: In the recent years comorbidity has been discussed as a factor affecting therapeutic decisions, the course of treatment, and prognosis of patients with lung cancer. The aim of the study was 1. to evaluate the occurrence of comorbidities in patients with lung cancer undergoing surgery, and 2. to investigate the utility of Charlson Comorbidity Index (CCI) and Simplified Comorbidity Score (SCS) for preoperative evaluation of Polish patients with lung cancer.

MATERIAL AND METHODS: The retrospective study included 476 patients with lung cancer, who underwent surgical treatment. In all patients, data on histopathological type of the tumor, stage, history of smoking, comorbidities, and spirometric parameters were collected. CCI and SCS scores were calculated. The presence of comorbidities was analyzed in relation to sex, histology, and stage of lung cancer. Correlations between CCI and SCS scores and age, number of pack-years, spirometric parameters were assessed.

RESULTS: The most prevalent comorbidities were hypertension (42%), chronic obstructive pulmonary disease (COPD) (22%), coronary heart disease (17%), and diabetes (12%). There were no differences in the distribution of comorbidity depending on the histological type and stage of lung cancer. The CCI and SCS scores showed correlations with age, number of pack-years and spirometric parameters, however, their compounds do not reflect the profile of most prevalent comoribidities.

CONCLUSION: The burden of comorbidity among patients with lung cancer is significant. Comorbidity should be assessed while considering patients for surgical treatment. However, the CCI and SCS do not seem precise enough for this purpose.

Abstract

INTRODUCTION: In the recent years comorbidity has been discussed as a factor affecting therapeutic decisions, the course of treatment, and prognosis of patients with lung cancer. The aim of the study was 1. to evaluate the occurrence of comorbidities in patients with lung cancer undergoing surgery, and 2. to investigate the utility of Charlson Comorbidity Index (CCI) and Simplified Comorbidity Score (SCS) for preoperative evaluation of Polish patients with lung cancer.

MATERIAL AND METHODS: The retrospective study included 476 patients with lung cancer, who underwent surgical treatment. In all patients, data on histopathological type of the tumor, stage, history of smoking, comorbidities, and spirometric parameters were collected. CCI and SCS scores were calculated. The presence of comorbidities was analyzed in relation to sex, histology, and stage of lung cancer. Correlations between CCI and SCS scores and age, number of pack-years, spirometric parameters were assessed.

RESULTS: The most prevalent comorbidities were hypertension (42%), chronic obstructive pulmonary disease (COPD) (22%), coronary heart disease (17%), and diabetes (12%). There were no differences in the distribution of comorbidity depending on the histological type and stage of lung cancer. The CCI and SCS scores showed correlations with age, number of pack-years and spirometric parameters, however, their compounds do not reflect the profile of most prevalent comoribidities.

CONCLUSION: The burden of comorbidity among patients with lung cancer is significant. Comorbidity should be assessed while considering patients for surgical treatment. However, the CCI and SCS do not seem precise enough for this purpose.

Get Citation

Keywords

lung cancer, comorbidity, Charlson Comorbidity Index, Simplified Comorbidity Score

About this article
Title

Comorbidity in patients undergoing surgery for lung cancer. Do we have an adequate tool to assess it?

Journal

Advances in Respiratory Medicine

Issue

Vol 85, No 2 (2017)

Pages

55-63

Published online

2017-03-12

DOI

10.5603/ARM.2017.0011

Bibliographic record

Adv Respir Med 2017;85(2):55-63.

Keywords

lung cancer
comorbidity
Charlson Comorbidity Index
Simplified Comorbidity Score

Authors

Marta Lembicz
Piotr Gabryel
Beata Brajer-Luftmann
Wojciech Dyszkiewicz
Halina Batura-Gabryel

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl